![Leigh Farrell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Leigh Farrell
Director/Board Member at
PRO MEDICUS LIMITED
Net worth: 629 498 $ as of 2026-06-29
Profile
Leigh Bernard Farrell is currently Chairman at Vitrafy Life Sciences Ltd. since 2025.
Serving as Independent Non-Executive Director at Pro Medicus Ltd. since 2017.
Managing Director & Executive Director at Adned Pty Ltd. Non-Executive Director at Ena Respiratory Pty Ltd. and Axelia Oncology Pty Ltd. since 2020.
Member of the Australian Institute of Co. Directors.
Former roles include Chief Executive Officer at Gene Shears Pty Ltd., Chairman & Chief Operating Officer at d3 Medicine LLC from 2014 to 2016, Associate Director at GBS Venture Partners Pty Ltd., Director at Cortical Pty Ltd., Research Manager at Johnson & Johnson Research Pty Ltd., Senior Vice President-Commercial at Certara USA, Inc. from 2018 to 2020, Vice President-Business Development at Aviragen Therapeutics, Inc. from 2006 to 2013, and Head-Health Security Division at DMTC Ltd. from 2021 to 2023.
Education includes undergraduate and doctorate degrees from Monash University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-06-29 | 4,240 ( 0% ) | 597 570 $ | 2026-06-29 | |
0.02% | 2026-02-18 | 15,311 ( 0.02% ) | 31 928 $ | 2026-06-29 |
Leigh Farrell active positions
| Companies | Position | Start |
|---|---|---|
| PRO MEDICUS LIMITED | Director/Board Member | 2017-09-07 |
Australian Institute of Co. Directors
 Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Promotes governance and develops leadership skills | Corporate Officer/Principal | - |
Adned Pty Ltd. | Chief Executive Officer | - |
Ena Respiratory Pty Ltd.
 Ena Respiratory Pty Ltd. BiotechnologyHealth Technology Develops novel synthetic innate immunomodulators for the prevention of respiratory viral and bacterial infections | Director/Board Member | 2020-07-31 |
Axelia Oncology Pty Ltd.
 Axelia Oncology Pty Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company aiming to transform the treatment of checkpoint insensitive cancers | Director/Board Member | 2020-07-31 |
Former positions of Leigh Farrell
| Companies | Position | End |
|---|---|---|
DMTC Ltd.
 DMTC Ltd. Founded in 2008, DMTC Ltd. is an Australian not-for-profit company that designs, manages, and leads collaborative multi-party research and development initiatives aimed at enhancing defence, national security, and health security capabilities while strengthening sovereign industrial capacity. The company is based in Hawthorn, Australia. The company works closely with government, industry, and research partners to deliver innovation-led programs across sector intelligence, industry uplift, science and technology programs, and innovation ecosystems, supported by education and training and its dedicated health security systems division. DMTC fosters research opportunities addressing challenges such as antimicrobial resistance and emergency response, and serves as a central hub connecting government, industry, and research sectors to advance strategic capabilities and the innovation ecosystem. | Corporate Officer/Principal | 2023-11-30 |
Certara USA, Inc.
 Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Provides drug development consultancy solutions | Corporate Officer/Principal | 2020-06-30 |
d3 Medicine LLC
 d3 Medicine LLC Pharmaceuticals: MajorHealth Technology Develops drugs and medicines | Chairman | 2016-11-30 |
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an anti-infective drug development company | Corporate Officer/Principal | 2013-11-30 |
| ░░░░ ░░░░░░ ░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
Training of Leigh Farrell
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
72
1st degree connections
14
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 14 |
|---|---|
Pro Medicus Ltd.
 Pro Medicus Ltd. Services to the Health IndustryHealth Services Develops and sells healthcare imaging software | Health Services |
Monash University
 Monash University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GBS Venture Partners Pty Ltd.
 GBS Venture Partners Pty Ltd. Investment ManagersFinance GBS Venture Partner seeks investment opportunities in private and public companies located in the United States, New Zealand and primarily in Australia. The firm targets companies operating in the fields of human healthcare, biotechnology, life science, biological/small molecule therapeutics, medical devices and diagnostics. It provides financing for seed, early and later stage capital requirements with an investment size ranging from of USD 10 to 12 million. It takes an active role on the board of directors and acts as a lead investor. It also makes co-investments. | Finance |
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Promotes governance and develops leadership skills | Commercial Services |
Johnson & Johnson Research Pty Ltd. | |
Cortical Pty Ltd.
 Cortical Pty Ltd. BiotechnologyHealth Technology Discovers and develops medical drugs | Health Technology |
Gene Shears Pty Ltd. | |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Provides drug development consultancy solutions | Commercial Services |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an anti-infective drug development company | Health Technology |
DMTC Ltd.
DMTC Ltd. Founded in 2008, DMTC Ltd. is an Australian not-for-profit company that designs, manages, and leads collaborative multi-party research and development initiatives aimed at enhancing defence, national security, and health security capabilities while strengthening sovereign industrial capacity. The company is based in Hawthorn, Australia. The company works closely with government, industry, and research partners to deliver innovation-led programs across sector intelligence, industry uplift, science and technology programs, and innovation ecosystems, supported by education and training and its dedicated health security systems division. DMTC fosters research opportunities addressing challenges such as antimicrobial resistance and emergency response, and serves as a central hub connecting government, industry, and research sectors to advance strategic capabilities and the innovation ecosystem. | |
d3 Medicine LLC
d3 Medicine LLC Pharmaceuticals: MajorHealth Technology Develops drugs and medicines | Health Technology |
Adned Pty Ltd. | |
Ena Respiratory Pty Ltd.
Ena Respiratory Pty Ltd. BiotechnologyHealth Technology Develops novel synthetic innate immunomodulators for the prevention of respiratory viral and bacterial infections | Health Technology |
Axelia Oncology Pty Ltd.
Axelia Oncology Pty Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company aiming to transform the treatment of checkpoint insensitive cancers | Health Technology |
- Stock Market
- Insiders
- Leigh Farrell
